CD16

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
Patient, Leiomyosarcoma, NK, Clinical trial, Male, Trial of the century, Neurodegenerative disease, Safety, CD16, MD, Cancer, NCR1, IP, Angiosarcoma, Fatigue, Society, Aes, NKG2D, Pharmaceutical industry

SANTA ANA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced an online publication, titled “Interim Analysis of a Phase I Study using Cryopreserved Non-genetically Modified Allogeneic Natural Killer Cells With Enhanced Cytotoxicity (SNK02) in Patients with Advanced Solid Tumors without Lymphodepletion” at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

Key Points: 
  • SNK02 was well tolerated as a monotherapy and appears to have some clinical activity against pretreated solid tumors despite the lack of lymphodepletion.
  • This Phase 1 clinical trial is a multi-center, open-label study evaluating the safety and tolerability of SNK02 in participants with pathologically confirmed solid tumors refractory to standard of care therapy.
  • SNK02 was administered as an intravenous infusion (IV), weekly for eight weeks in patients with advanced solid tumors.
  • SNK02 was well tolerated as a monotherapy and appears to have some clinical activity against pretreated solid tumors despite the lack of lymphodepletion.

OncoC4 Announces FDA Clearance of IND Application for Novel SIGLEC 10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors

Retrieved on: 
tisdag, april 23, 2024
Cancer, Cell, Safety, Pharmacokinetics, Tumor microenvironment, Doctor of Philosophy, IND, Knowledge, Entrepreneurship, ADCC, Phagocytosis, Macrophage, CSO, CD16, NK, SIGLEC, TME

“SIGLEC 10 is an immune checkpoint that inhibits the activation of both innate and adaptive immune cells.

Key Points: 
  • “SIGLEC 10 is an immune checkpoint that inhibits the activation of both innate and adaptive immune cells.
  • “ONC-841 is designed to block this immune checkpoint to rejuvenate immune cell activity for tumor destruction within the TME.
  • Preclinical studies supporting the IND application demonstrated ONC-841 increased the phagocytosis of cancer cells and improved the function of tumor-infiltrating T cells.
  • Additional in vivo syngeneic and xenograft tumor models showed enhanced immune rejection of tumor cells following treatment with ONC-841.

NMDP BioTherapies Introduces Enhanced Cellular Materials for Allogeneic Cell Therapy Development

Retrieved on: 
tisdag, april 16, 2024
Health, Health Technology, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, RUO, CBUS, CBU, Investment, NMDP, Match, Collection, Research, KIR, Drug Master File, Cryopreservation, Patient, GMP, DMF, CD16, Organization, Medical device

NMDP BioTherapies ℠, formerly Be The Match BioTherapies, a leader in cell and gene therapy development support, unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings.

Key Points: 
  • NMDP BioTherapies ℠, formerly Be The Match BioTherapies, a leader in cell and gene therapy development support, unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings.
  • “We have leveraged over three decades of experience in managing cellular product collections, working closely with cell and gene therapy developers to deliver an advanced allogeneic suite of compliant products,” said Tom Hochuli, President of NMDP BioTherapies.
  • “These investments in our cellular starting material offerings are a testament to our commitment to advancing the cell and gene therapy industry.
  • Recognizing the diverse stages of cell therapy development, NMDP BioTherapies has broadened its RUO leukopak capabilities.

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Retrieved on: 
torsdag, mars 14, 2024
CD33, GSK, Patient, Macrophage, Society, CD3, CD47, DLL3, Therapy, Molecular Partners, TME, Partner, DRS, ASH, AML, SNMMI, Partnership, RDT, Radionuclide, Tetra, Novartis, HSCT, MHS, FTE, Exposition, Delta, Safety, SITC, Amgen, Hematopoietic stem cell transplantation, FAP, Disease, Nuclear medicine, Immunotherapy, District court, Neoplasm, EANM, Alpha particle, JNJ, Tumor microenvironment, Gene family, CD70, AACR, CD40, CHF, CD123, NK, Engineering, Antigen, Molecule, Annual general meeting, Toxicity, CD16, B cell, Conference, MBA, DARPin, Data, Molecular imaging, Pharmaceutical industry

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.
  • “2023 was a year of successful innovation and execution on our strategy, focusing on novel mechanisms that we believe only DARPin therapies can deliver.
  • In addition to the above updates, Molecular Partners continued to progress its RDT portfolio of projects in partnership with Novartis.
  • In the financial year 2023, Molecular Partners recognized total revenues and other income of CHF 7.0 million (2022: CHF 189.6 million) and incurred total expenses of CHF 68.1 million (2022: CHF 73.0 million).

Biosion to Present Three Posters at the 2024 AACR Meeting

Retrieved on: 
torsdag, mars 21, 2024
HER2, Malignancy, CD16, Trastuzumab, Head, B cell, Cancer, Patient, BTN3A3, IND, AACR, BTN3A1, Cholangiocarcinoma, CD40, NK, Vaccine

"We are thrilled to present three posters at the AACR annual meeting.

Key Points: 
  • "We are thrilled to present three posters at the AACR annual meeting.
  • BSI-111 binds specifically to CD16a without recognizing CD16b and binds the two allelic variants of CD16A - 158F and 158V with similar high affinity.
  • Additionally, Biosion's partner, CTTQ Pharma, OBI Pharma and Pyxis Oncology, will also be presenting posters at the AACR meeting.
  • In 2019, Biosion licensed Greater China rights of BSI-038 to CTTQ and retains all rights for development and commercialization in the rest of the world.

Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma

Retrieved on: 
onsdag, mars 6, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, CD20, IPH, CD16, NHL, NCR1, Relapse, IPHA, Safety, Therapy, Patient, NK, Euronext Paris, Pharmaceutical industry

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its Phase 1/2 multicenter trial ( NCT06088654 ), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma (NHL).

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its Phase 1/2 multicenter trial ( NCT06088654 ), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma (NHL).
  • The study is planned to enroll up to 184 patients.
  • “We are pleased to announce the dosing of a first patient in this Phase 1/2 study evaluating IPH6501, our proprietary ANKET® asset and the first tetraspecific NK Cell Engager to enter the clinic.” commented Dr Sonia Quaratino, Chief Medical Officer at Innate Pharma.
  • In this context, IPH6501 represents an innovative option for the treatment of patients with R/R B-cell non-Hodgkin’s lymphomas and has the potential to fulfil a large unmet need.”

Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors

Retrieved on: 
måndag, januari 8, 2024
Partnership, Tumor microenvironment, Immunotherapy, HER2, Trastuzumab, CD8, CXCR2, IPSC, SAN, Therapy, Pharmacokinetics, Destiny, CD16, Patient, Safety, Vaccine

SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced the initiation of enrollment for its Phase 1 clinical trial of FT825 / ONO-8250, a multiplexed-engineered, chimeric antigen receptor (CAR) T-cell product candidate targeting human epidermal growth factor receptor 2 (HER2). The iPSC-derived CAR T-cell product candidate incorporates a novel HER2-targeted antigen binding domain and is designed to overcome unique challenges in treating solid tumors. The Phase 1 study of FT825 / ONO-8250 is being conducted under a strategic collaboration with Ono Pharmaceutical Co., Ltd. (Ono).

Key Points: 
  • The iPSC-derived CAR T-cell product candidate incorporates a novel HER2-targeted antigen binding domain and is designed to overcome unique challenges in treating solid tumors.
  • The Phase 1 study of FT825 / ONO-8250 is being conducted under a strategic collaboration with Ono Pharmaceutical Co., Ltd. (Ono).
  • The Phase 1 study is designed to investigate a single dose of FT825 / ONO-8250 as monotherapy and in combination with monoclonal antibody therapy in previously-treated patients with advanced solid tumors.
  • The parties are currently conducting preclinical development of an additional solid tumor program targeting an undisclosed tumor-associated antigen.

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
söndag, januari 7, 2024
NAMD, Conference, Gene family, Partnership, Neoplasm, Tumor microenvironment, IND, Hematopoietic stem cell transplantation, Radionuclide, CD47, Data, Myelodysplastic syndrome, Macrophage, Molecular Partners, HSC, Society, CHF, Novartis, ASH, COVID-19, DARPin, Toxicity, RDT, CD16, Stem cell, HSCT, Patient, Acute myeloid leukemia, Safety, Therapy, AML, DLL3, Health, SITC, Pharmaceutical industry

53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.
  • Data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023.
  • Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.
  • In addition to these updates, Novartis has returned the rights to the ensovibep program, previously under investigation for the treatment of COVID-19, to Molecular Partners.

Supercell Acquires Exclusive Licensing from Japanese Immunotherapy Leader for Advanced NK Cell Treatment Technology

Retrieved on: 
måndag, december 4, 2023
Immune system, CD16, AIET, Stem cell, Patient, Multimedia, Regenerative medicine, CD56, Biotechnology, Supercell, NHS, PMID, Trial of the century, Cancer, Colorectal cancer, Cell, Face, NK, Vaccine, Pharmaceutical industry, Fertilizer

Supercell, through partnerships in regenerative medicine, has secured an exclusive license for a Japanese-developed natural killer (NK) cell culture technique.

Key Points: 
  • Supercell, through partnerships in regenerative medicine, has secured an exclusive license for a Japanese-developed natural killer (NK) cell culture technique.
  • The technique, pivotal in cancer cell elimination and immune system enhancement, will be showcased at the expo, highlighting their latest experimental advancements[1].
  • Dr. Hiroshi Terunuma, a distinguished international authority in cancer treatment based in Japan and a long-standing partner of Supercell, has successfully administered NK cell therapy in over 40,000 cases.
  • In a clinical study, 63 patients diagnosed with terminal malignant pancreatic cancer received conventional cancer therapy supplemented by NK cell infusion.

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Retrieved on: 
onsdag, november 8, 2023
Food, Multiple myeloma, CXCR2, Enrollment, B-cell lymphoma, Lupus, SITC, Cetuximab, Annual general meeting, Rituximab, SLE, CAR, Hyperbaric treatment schedules, GAAP, Graft-versus-host disease, Safety, Cancer, Therapy, Ono Pharmaceutical, Investment, Patient, IPSC, Society for Immunotherapy of Cancer, Chronic lymphocytic leukemia, Research, Immunotherapy, TRAC, CD16, NK, Clinical trial, Multiplexing, BCL, Acute leukemia, CRS, Cell, FDA, Trastuzumab, IND, ONO, ADR, HER2, Neoplasm, Protocol, Lupus Research Alliance, Destiny, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmacokinetics, Tumor microenvironment, BCMA, Vaccine, Pharmaceutical industry, Autoimmunity

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today reported business highlights and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • FT522 is the Company’s off-the-shelf, multiplexed-engineered natural killer (NK) cell product candidate that incorporates five synthetic controls of cell function.
  • In addition, as of September 30, 2023, cash receivables from the Company’s collaboration with ONO were $1.5 million.
  • Shares Outstanding: Common shares outstanding were 98.6 million, and preferred shares outstanding were 2.8 million, as of September 30, 2023.
  • ET to review financial and operating results for the quarter ended September 30, 2023.